Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CU
Clinuvel Pharmaceuticals Limited American Depositary Shares
CUVL
Mkt Cap
$264.3M
Volume
3.23K
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CU
CUVL
CU
Clinuvel Pharmaceuticals Limited American Depositary Shares
CUVL
News
·
A decade of profitability provides foundation for CLINUVEL’s U.S. expansion
Mkt Cap
$264.3M
Volume
3.23K
Next Earnings
N/A
Chart
Earnings
News
About
Dividends
Insider
Filings
A decade of profitability provides foundation for CLINUVEL’s U.S. expansion
CLINUVEL Pharmaceuticals announced its tenth consecutive annual profit for FY2026 with revenues of $94.0 million and net profit after tax of $33.9 million. The company declared a $0.05 per share dividend and increased cash reserves to $252.1 million, providing financial independence to pursue expansion strategy, particularly in North America. Despite marginal revenue decline due to U.S. market competition and inventory practice changes, the company maintained disciplined expense control and achieved record SCENESSE treatment volumes.
GlobeNewswire Inc. · Aug 27, 2026
CLINUVEL implements strategic reorganisation to refocus on U.S. markets
CLINUVEL Pharmaceuticals announced a strategic reorganisation effective January 1, 2027, relocating its corporate headquarters from Australia to the United States and reducing its global workforce by 10-20%. The restructuring aims to strengthen U.S. regulatory engagement, focus operations on the U.S. pharmaceutical market, and unlock deeper capital pools from U.S. investors who prefer U.S.-listed companies. The move is driven by the company's recognition that U.S.-listed specialty pharma companies command higher valuation multiples and that over 66% of its shareholder base is already foreign investors.
GlobeNewswire Inc. · Jul 23, 2026
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CU
CUVL
Clinuvel Pharmaceuticals Limited American Depositary Shares
Buy
Sell
Market
Limit
Soon
CUVL
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CUVL yet.
Related Tickers
Earnings
Dividends
Last · Sep 8
Annual
Amount
$0.0360
Yield
0.69%
Annual
$0.0360